MPA/DMBA-driven mammary carcinomas.

摘要: Abstract The polycyclic aromatic hydrocarbon 7,12-dimethylbenz[a]anthracene (DMBA, D) administered per os to wild-type female mice bearing slow-release medroxyprogesterone (MPA, M) pellets s.c. drives the formation of mammary carcinomas that recapitulate numerous immunobiological features human luminal B breast cancer. In particular, M/D-driven established in immunocompetent C57BL/6 (1) express hormone receptors, (2) emerge by evading natural immunosurveillance and hence display a scarce immune infiltrate largely polarized toward immunosuppression, (3) exhibit exquisite sensitivity CDK4/CDK6 inhibitors, (4) are resistant immunotherapy with checkpoint blockers targeting PD-1. Thus, evolving stand out as privileged preclinical platform for study Here, we provide detailed protocol establishment mice. This can be easily adapted generate most genetic backgrounds (including genetically-engineered mice).